Detalhe da pesquisa
1.
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.
Cancer Immunol Immunother
; 72(7): 2459-2471, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016127
2.
Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.
Cancer Immunol Immunother
; 61(10): 1683-97, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22392192
3.
Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.
Mol Immunol
; 66(2): 208-15, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25829245
4.
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Int Immunopharmacol
; 17(4): 1141-7, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24201083
5.
Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
J Immunother
; 36(1): 29-40, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23211623
6.
Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
J Immunother
; 34(1): 76-84, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21150715